KT-579

N/A

Report date: 2026/02/28 20:00:37
NMEFirst In Class

Base Information

Drug NameKT-579
Drug Alias NameKT-579
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionInterferon regulatory factor 5 degraders
TargetsInterferon regulatory factor 5
Therapy Area/IndicationsScleroderma, SystemicInflammatory Bowel DiseasesDermatomyositis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKymera Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKymera Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicInflammatory Bowel DiseasesDermatomyositis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A